Show simple item record

dc.contributor.authorRabeneck, L.
dc.contributor.authorLansdorp_Vogelaar, Iris
dc.date.accessioned2017-03-17T08:28:45Z
dc.date.available2017-03-17T08:28:45Z
dc.date.created2017-02-19T19:31:48Z
dc.date.issued2015
dc.identifier.citationRabeneck, L. and Lansdorp_Vogelaar, I. 2015. Assessment of a cancer screening program. Best Practice and Research: Clinical Gastroenterology. 29 (6): pp. 979-985.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/50829
dc.identifier.doi10.1016/j.bpg.2015.09.009
dc.description.abstract

Several Asian countries are implementing nationwide cancer screening programs. Assessment of the effectiveness of these programs is critical to their success as this is the only way to ensure that the benefits of screening outweigh the harms. In this paper we focus on colorectal cancer (CRC) screening to illustrate the principles of screening program assessment. The International Agency for Research on Cancer (IARC) has defined organized screening, distinguishing it from opportunistic screening. The key advantage of organized screening is that it provides greater protection against the possible harms of screening. Since screening is a process, not simply a test, the effectiveness of a program depends on the quality of each step in the cancer screening process. The evaluation of long-term screening program outcomes (CRC incidence and mortality) will not be observable for many years, given the time it takes to plan, pilot and implement a program. However, early performance indicators of the impact of screening should be monitored to give an early indication whether the program is on track. The European Union (EU) has recommended a minimum dataset to be collected and reported regularly by a screening program. Using information from these data tables, early performance indicators can be generated (e.g., participation rate, proportion of screen-detected cancers that are early-stage). Subsequently, modeling the natural history of the disease can be very helpful to estimate long-term outcomes, making use of these directly measured early performance indicators. Modeling can also be used to estimate the cost-effectiveness of a screening program and the potential impact of changes in policy, as illustrated by its recent use in the Netherlands to change the definition of a positive fecal immunochemical test (FIT) for the CRC screening program. Programs should consider modeling as an important component of screening program evaluation.

dc.titleAssessment of a cancer screening program
dc.typeJournal Article
dcterms.source.volume29
dcterms.source.number6
dcterms.source.startPage979
dcterms.source.endPage985
dcterms.source.issn1521-6918
dcterms.source.titleBest Practice and Research: Clinical Gastroenterology
curtin.accessStatusFulltext not available


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record